Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its
Drug Substances service offering

   Siegfried AG / Key word(s): Acquisition
   Siegfried to acquire an early-phase CDMO in Wisconsin (US) to
   strengthen its Drug Substances service offering
   12-Jun-2024 / 06:30 CET/CEST
   Release of an ad hoc announcement pursuant to Art. 53 LR
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   
     * Siegfried to acquire a CDMO specialized in early-phase
       development and manufacturing services in Grafton, Wisconsin
       (US)
     * The new site is set to strengthen Siegfried's customer
       offering for Drug Substances in terms of capabilities and
       geography
     * Siegfried will further develop the site into its North
       American Siegfried Acceleration Hub for early-phase CDMO
       services, to generate attractive growth opportunities

   Siegfried (SIX: SFZN), a leading global Contract Development and
   Manufacturing Organization (CDMO) for the pharmaceutical industry
   headquartered in Zofingen (Switzerland), has signed binding
   agreements with Curia Global for the acquisition of an
   early-phase CDMO site in Grafton, Wisconsin (US).

   The new site, which specializes in early-phase development and
   manufacturing services with an experienced team of more than 80
   employees, is set to strengthen Siegfried's customer offering for
   Drug Substances in terms of capabilities and geographical
   coverage. Siegfried intends to develop the site into a
   best-in-class hub for early-phase CDMO services for its global
   customer base, including services for projects with highly potent
   APIs. Subject to customary closing conditions, the transaction is
   expected to close by July 1, 2024.

   Reto Suter, CEO ad interim and CFO of Siegfried, commented: 'With
   this acquisition, we enhance our offering with early-stage
   development services for Drug Substances and become even more
   relevant and attractive to our customers. Siegfried now offers an
   integrated range of services from early-stage development to
   commercial production of APIs through to the manufacturing of
   fully formulated Drug Products. This transaction will generate
   attractive opportunities and will further accelerate our growth
   story.'

   The acquisition will strengthen Siegfried's position in the
   United States, the world's largest pharmaceutical market, and
   enables Siegfried to provide comprehensive support to customers
   in the pre-clinical and clinical development and manufacturing of
   Drug Substances. This further expands Siegfried's offering,
   particularly for small and medium-sized pharmaceutical companies.
   The focus on early-phase CDMO services will further strengthen
   Siegfried's Drug Substance pipeline by capturing additional
   attractive opportunities in their early stage, creating
   significant growth opportunities in the future.

   The acquisition is financed from existing funds. The outlook for
   2024 and the mid-term financial targets remain unchanged.

Media Release English version (PDF)

Media Release German version (PDF)

Analyst Call

   Siegfried will host an analyst call on June 12 at 10:00 am CEST.
   To participate in the analyst call, please follow the dial-in
   information below.

Analyst Call presentation (PDF)

Click here to join the meeting

Meeting ID: 359 199 908 234

Passcode: iCWXMQ



Dial in by phone

+41 43 216 37 72,,740164912# Switzerland, Zurich/Zürich/Zurigo

Find a local number

Phone conference ID: 740 164 912#

Further Information

Media release on website

Contact

   Financial Analysts:     Media:
   Dr. Reto Suter          Peter Stierli
   Chief Financial Officer Head Corporate Communications
   reto.suter@siegfried.ch peter.stierli@siegfried.ch
   Tel. +41 62 746 11 35   Tel. +41 62 746 15 51

Siegfried Holding AG

Untere Bruehlstrasse 4

CH-4800 Zofingen



About Siegfried

   The Siegfried Group is a global life sciences company with sites
   in Switzerland, Germany, Spain, France, Malta, the USA and China.
   In 2023, the company achieved sales of CHF 1.272 billion and
   employed on 31.12.2023 more than 3700 people at twelve sites on
   three continents. Siegfried Holding AG is publicly listed on the
   SIX Swiss Exchange (SIX: SFZN).

   Siegfried is active in manufacturing pharmaceutical APIs (and
   their intermediates) as well as drug products (tablets, capsules,
   sterile vials, ampoules, cartridges and ointments) for the
   pharmaceutical industry and provides development services.
   Cautionary Statements Regarding Forward-Looking Statements
   This media release includes statements concerning the future.
   They are based on assumptions and expectations that may prove to
   be wrong. They should be considered with due caution as, by
   definition, they contain known and unknown risks, insecurities
   and other factors which could result in a difference in the
   actual results, financial situation, developments or the success
   of Siegfried Holding AG or Siegfried Group from the explicit or
   implicit assumptions made in these statements.

expect more

   Siegfried AG
   Untere Brühlstrasse 4
   4800 Zofingen, Switzerland
   +41 62 746 11 11
   info@siegfried.ch
   www.siegfried.ch

   Additional features:
   File:
   https://eqs-cockpit.com/c/fncls.ssp?u=3765c4e2cf467e2475c0fd9bd61f4a72
   File:
   https://eqs-cockpit.com/c/fncls.ssp?u=3087235d534529b18dc84ded67b74e49
   File:
   https://eqs-cockpit.com/c/fncls.ssp?u=d16aca7c55440d15b263ed5d9a271b6d
     ____________________________________________________________

   End of Inside Information
     ____________________________________________________________

   Language:    English
   Company:     Siegfried AG
                Untere Brühlstrasse 4
                4800 Zofingen
                Switzerland
   Phone:       +41 62 746 11 11
   E-mail:      info@siegfried.ch
   Internet:    https://www.siegfried.ch
   ISIN:        CH0014284498
   Listed:      SIX Swiss Exchange
   EQS News ID: 1915639

   End of Announcement EQS News Service
     ____________________________________________________________

1915639 12-Jun-2024 CET/CEST